porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2013341-42porozendo-8867Research ArticleСтатьиArticlesАНАЛИЗ ПОСЛЕДНИХ ПУБЛИКАЦИЙ АМЕРИКАНСКОГО ОБЩЕСТВА ИССЛЕДОВАНИЯ КОСТНОГО И МИНЕРАЛЬНОГО ОБМЕНА (ASMBR) 2013PROLIA (DENOSUMAB): ANALYSIS OF RECENT PUBLICATIONS FROM THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH (ASMBR) MEETING 2013ПигароваЕ АPigarovaE A

к.м.н., с.н.с. отделение нейроэндокринологии и остеопатий

kpigarova@gmail.comФГБУ «Эндокринологический научный центр» Минздрава Российской Федерации201315122013163№3 (2013)4142Copyright © Пигарова Е.А., 20132013Пигарова Е.А.Pigarova E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/8867

4—7 октября 2013 года в Балтиморе (США) прошел ежегодный съезд Американского общества исследования костного и минерального обмена (ASMBR), на котором много публикаций было посвящено деносумабу, препарату человеческих моноклональных антител к основному патогенетическому звену развития остеопороза RANK-лиганду, инактивация которого приводит к резкому подавлению костной резорбции, созданию благоприятных условий для восстановления костной ткани и выраженному снижению риска переломов. Некоторые из работ, представленных на съезде, заслуживают отдельного внимания и обсуждаются в данной публикации. Приведенные исследования добавляют новые краски в общую картину особенностей действия деносумаба, свидетельствующие об эффективности препарата при длительном лечении на подавление костной резорбции, прирост МПК, снижение риска переломов, улучшении качества кортикальной ткани, сохранении нормальных ультраструктурных параметров кости.

On October 4—7, 2013 Baltimore (USA) hosted the Annual Congress of the American Society for Bone and Mineral Research (ASMBR), during which many publications were devoted to denosumab, a human monoclonal antibody to the main pathogenic link of osteoporosis — RANK-ligand, which results in a dramatic suppression of bone resorption, creating favorable conditions for the restoration of bone and a marked reduction in fracture risk. Some of the papers presented at the Congress deserve special attention and are discussed in this publication. These studies add new colors to the overall picture of denosumab action, showing efficacy of long-term treatment to suppress bone resorption, increase BMD, reduce fracture risk, improvement in the quality of the cortical bone tissue, ultrastructuralpreservation of normal bone parameters.

деносумабRANK-лигандостеопорозминеральная плотностью костиМПКрезорбцияпереломыкортикальная тканьASMBRASMBRdenosumabRANK- ligandosteoporosisbone mineral densityBMDresorptionfracturescortical tissueReferencesFerrari S, Adachi JD, Zapalowski C, Miller PD, Reginster J-Y, Törring O, Daizadeh N, Wang A, O'Malley C, Wagman RB, Lewiecki EM. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=fbe10568-7794-42ff-b8f4-11be524425a1. Accessed December 5, 2013.Ferrari S, Adachi JD, Zapalowski C, Miller PD, Reginster J-Y, Törring O, Daizadeh N, Wang A, O'Malley C, Wagman RB, Lewiecki EM. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=fbe10568-7794-42ff-b8f4-11be524425a1. Accessed December 5, 2013.Genant HK, Keaveny TM, Zapalowski C, Engelke K, Fuerst T, Kendler DL, Recknor C, Boonen S, Wang A, Dakin P, Libanati C, McClung MR. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis №75 and >75 years old. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstractdetail?aid=8c52b2ea-026e-4b62-97af-c95b922f85da. Accessed December 5, 2013.Genant HK, Keaveny TM, Zapalowski C, Engelke K, Fuerst T, Kendler DL, Recknor C, Boonen S, Wang A, Dakin P, Libanati C, McClung MR. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis №75 and >75 years old. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstractdetail?aid=8c52b2ea-026e-4b62-97af-c95b922f85da. Accessed December 5, 2013.Papapoulos S, Lippuner K, Roux C, Hall J, Kendler D, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Geller M, Wagman RB, Bone HG. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=4e003dea-3d2d-4ae5-9f4e-777f089e5876. Accessed December 5, 2013.Papapoulos S, Lippuner K, Roux C, Hall J, Kendler D, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Geller M, Wagman RB, Bone HG. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=4e003dea-3d2d-4ae5-9f4e-777f089e5876. Accessed December 5, 2013.Brown JP, Bolognese MA, Ho P-R, Hall J, Roux C, Bone HG, Bonnick S, van den Bergh J, Ferreira I, Ghelani P, Dakin P, Wagman RB, Recknor C. Denosumab significantly increases bone mineral density compared with ibandronate and risedronate in postmenopausal women previously treated with an oral bisphosphonate who are at higher risk for fracture. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www. asbmr.org/asbmr-2013-abstract-detail?aid=47b5654a-5815-412d-a226-138e5a0c71b2. Accessed December 5, 2013.Brown JP, Bolognese MA, Ho P-R, Hall J, Roux C, Bone HG, Bonnick S, van den Bergh J, Ferreira I, Ghelani P, Dakin P, Wagman RB, Recknor C. Denosumab significantly increases bone mineral density compared with ibandronate and risedronate in postmenopausal women previously treated with an oral bisphosphonate who are at higher risk for fracture. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www. asbmr.org/asbmr-2013-abstract-detail?aid=47b5654a-5815-412d-a226-138e5a0c71b2. Accessed December 5, 2013.Dempster D, Kendler DL, Hall J, Boonen S, Bolognese M, Chapurlat R, Goemaere S, Hyldstrup L, Lewiecki EM, Miller P, Yang Y-C, Wagman RB, Langdahl B. Effect of denosumab treatment on bone histology and histomorphometry in men with low bone mineral density. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/ asbmr-2013-abstract-detail?aid=83536378-0e27-431e-9e7f-cd9a7564b-deb. Accessed December 5, 2013.Dempster D, Kendler DL, Hall J, Boonen S, Bolognese M, Chapurlat R, Goemaere S, Hyldstrup L, Lewiecki EM, Miller P, Yang Y-C, Wagman RB, Langdahl B. Effect of denosumab treatment on bone histology and histomorphometry in men with low bone mineral density. J Bone Miner Res 2013, 28 (Suppl 1). Available at http://www.asbmr.org/ asbmr-2013-abstract-detail?aid=83536378-0e27-431e-9e7f-cd9a7564b-deb. Accessed December 5, 2013.

The authors declare that there are no conflicts of interest present.